Hideo Toyoshima

This inventor holds 8 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Nec Corporation, Nec Electronics Corporation, Saitama Medical University. Active years: 1990-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideo Toyoshima. Retrieved from https://idiyas.com/inventor/hideo-toyoshima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Tokyo, JP (1990 - 2012)
Saitama, JP (2018)

Company Filing History:

Nec Electronics Corporation

patents

2 out of 34

Saitama Medical University

patents

Years Active: 1990-2018

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9856304 - Peptide and application thereof (2018-01-02),

2. 8236758 - Method of treatment of diabestes or reduction in pancreatic beta-cells (2012-08-07),

3. 6731530 - Shadow RAM cell using a ferroelectric capacitor (2004-05-04),

4. 6654273 - Shadow ram cell using a ferroelectric capacitor (2003-11-25),

5. 6646909 - Memory cell, nonvolatile memory device and control method therefor improving reliability under low power supply voltage (2003-11-11),

6. 5703815 - High-speed semiconductor memory system (1997-12-30),

7. 5694367 - Semiconductor memory operable with low power supply voltage (1997-12-02),

8. 4926232 - Resonant-tunneling bipolar transistor (1990-05-15),

Title: Hideo Toyoshima: Innovator in Peptide Research

Introduction

Hideo Toyoshima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of peptide research, holding a total of 8 patents. His work focuses on innovative solutions for medical applications, particularly in the treatment of diabetes.

Latest Patents

Toyoshima's latest patents include a groundbreaking peptide and its applications. This new peptide comprises an amino acid sequence set forth in SEQ ID NO: 1, or variations thereof. The peptide, along with a vector that inserts DNA coding for it, is designed for promoting the proliferation of pancreatic hormone-producing cells. Additionally, it serves as a differentiation induction promoter for these cells. Another notable patent involves methods for treating diabetes and increasing pancreatic beta-cells. This includes an insulin secretion inducer and a composition aimed at enhancing the number of pancreatic beta-cells, utilizing a polypeptide encoded by a specific membrane protein.

Career Highlights

Throughout his career, Toyoshima has worked with notable companies such as NEC Corporation and NEC Electronics Corporation. His experience in these organizations has contributed to his expertise in peptide research and development.

Collaborations

Some of Toyoshima's coworkers include Tohru Miwa and Shigeru Kuhara. Their collaborative efforts have further advanced the research and applications of peptides in medical science.

Conclusion

Hideo Toyoshima's innovative work in peptide research has the potential to significantly impact the treatment of diabetes and related conditions. His contributions to the field are marked by a series of valuable patents that reflect his dedication to advancing medical science.

Profile summary based on public USPTO records.